Home › Research › Treatments
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K et al.. The New England journal of medicine, 2023-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively. Conclusions Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline.
What this study adds
Evidence grade: Low
This is a trial of 980 participants. In two phase 3 trials, gantenerumab lowered amyloid plaque burden more than placebo at 116 weeks but was not associated with slower clinical decline. Reported effect size: 28.0%; 26.8%; 24.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bateman, R. J., Smith, J., Donohue, M. C., Delmar, P., Abbas, R., Salloway, S., et al. (2023). Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. https://doi.org/10.1056/nejmoa2304430
Vancouver
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. 2023. doi:10.1056/nejmoa2304430. PMID: 37966285.
BibTeX
@article{bateman2023-37966285,
author = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others},
title = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}},
journal = {The New England journal of medicine},
year = {2023},
doi = {10.1056/nejmoa2304430},
pmid = {37966285},
url = {https://doi.org/10.1056/nejmoa2304430}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results A total of 985 and 980 participants were enrolled in the GRADUATE I and II trials, respectively.
- Conclusions Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline.
Why it matters
In two phase 3 trials, gantenerumab lowered amyloid plaque burden more than placebo at 116 weeks but was not associated with slower clinical decline. This means the drug did not slow the clinical course of early Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants980
- Effect size28.0%; 26.8%; 24.9%
- Evidence strengthLow
How this study scored 81/100
Published in a top-tier journal, and it is a large phase 3 trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The New England journal of medicine) |
| Journal's citation record | 4 / 4 | New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 980 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 6 / 7 | Cited 306 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 61.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 6 / 6 | Cited 44.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 29 other studies in this library |
| Still being cited | 4 / 4 | Cited 303 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rachelle Smith Doody: h-index 97 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 24 institution(s) in 9 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37966285) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1056/nejmoa2304430
- PubMed: 37966285
- Original source →
- Free full text: UCL Discovery (University College London) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
29 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.